Author: Tuccori, Marco; Ferraro, Sara; Convertino, Irma; Cappello, Emiliano; Valdiserra, Giulia; Blandizzi, Corrado; Maggi, Fabrizio; Focosi, Daniele
Title: Anti-SARS-CoV-2 neutralizing monoclonal antibodies: clinical pipeline Cord-id: glmp1uz1 Document date: 2020_12_15
ID: glmp1uz1
Snippet: Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those
Document: Monoclonal antibody (mAb) therapy has been previously exploited for viral infections, such as respiratory syncytial virus pneumonia and Ebolavirus disease. In the ongoing COVID-19 pandemic, early signals of efficacy from convalescent plasma therapy have encouraged research and development of anti-SARS-CoV-2 mAbs. While many candidates are in preclinical development, we focus here on anti-SARS-CoV-2 neutralizing mAbs (or mAb cocktails) that represent the late-stage clinical pipeline, i.e., those currently in Phase 2 or Phase 3 clinical trials. We describe the structure, mechanism of action, and ongoing trials for VIR-7831, LY-CoV555, LY-CoV016, BGB-DXP593, REGN-COV2, and CT-P59. We speculate also on the next generation of these mAbs.
Search related documents:
Co phrase search for related documents- acceptable risk benefit ratio show and action mechanism: 1
Co phrase search for related documents, hyperlinks ordered by date